A Phase 2 interventional study of MBA-P01 (Botulinum toxin A) and Placebo in Glabellar Frown Lines, sponsored by Medy-Tox. Completed at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-19.
Sponsored by Medy-Tox · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will determine the effect of MBA-P01 in subjects with glabellar lines at a range of doses compared with placebo.
This study includes two treatment period; 1) Dose-ranging period, Day0 to 16weeks and 2) Open-label extension period, 16 weeks to 52.
Medy-Tox is the lead sponsor of 49 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Experimental group, Dose: 30U
Drug: MBA-P01 (Botulinum toxin A)
Experimental group, Dose: 20U
Drug: MBA-P01 (Botulinum toxin A)
Experimental group, Dose: 10U
Drug: MBA-P01 (Botulinum toxin A)
Placebo group, Normal saline
Drug: Placebo
Intramuscular injection, dose varies by groups
Intramuscular injection
Facial Wrinkle Scale(FWS) change
Proportion of subjects achieving at least a 2-grade decrease from baseline in score of Facial Wrinkle Scale (FWS) (0:none to 3: severe) of Glabellar line at maximum frown
Time frame: 4 weeks
Ran from May 2019 to primary completion in Sep 2020, 15 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A